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Background: Hypertension (EH) and type 2 diabetes (T2DM) are major causes of chronic kidney disease (CKD) and
identification of predictors of CKD onset is advisable. We aimed to assess whether dynamic renal resistive index
(DRIN), as well as other markers of systemic vascular damage, are able to predict albuminuria onset and estimated
glomerular filtration rate (eGFR) decline in patients with T2DM or EH.
Methods: In this prospective observational cohort study, 27 T2DM and 43 EH patients, free of CKD at baseline, were
followed-up for 4.1 ± 0.6 years. Resistive Index (RI), endothelium-dependent (FMD) and independent vasodilation in
the brachial artery (after glyceryl trinitrate – GTN - 25 μg s.l.), carotid-femoral Pulse Wave Velocity (PWV), Augmentation
Index (AIx), DRIN (%RI change after GTN 25 μg s.l.) were evaluated.
Results: Patients developing microalbuminuria were older, more frequently T2DM, with higher UACR at baseline,
and showed higher DRIN (−2.8 ± 6.7 vs −10.6 ± 6.4 %, p = 0.01) and PWV (9.9 ± 1.3 vs 7.9 ± 1.5 m/s, p = 0.004) at
baseline. The best predictors of microalbuminuria onset were DRIN > −5.16 % in T2DM (sensitivity 0.83, specificity
0.80) and PWV > 8.6 m/s in EH (sensitivity 0.96, specificity 1.00). Individuals whose eGFR declined (n = 27) had higher
eGFR at baseline, but similar vascular characteristics; however in EH showing eGFR decline, baseline DRIN and PWV
were higher. PWV showed a steeper progression during follow-up in patients developing albuminuria (Visit-outcome
interaction: p = 0.01), while DRIN was early compromised but no further impaired (Visit-outcome interaction: p = 0.04).
Conclusions: PWV and DRIN are able to predict microalbuminuria onset in newly diagnosed EH and T2DM. DRIN is
early compromised in T2DM patients developing microalbuminuria.
Keywords: Renal resistive index, Hypertension, Type 2 diabetes, Arterial stiffness, Renal outcome, Prospective study,
MicroalbuminuriaBackground
Chronic kidney disease (CKD) is a major cause of cardio-
vascular morbidity and mortality, with hypertension and
type 2 diabetes (T2DM) representing the most relevant
risk factors for its development in western countries [1].
Both increased albumin excretion and reduction in glom-
erular filtration rate are associated with increased inci-
dence of all-cause and cardiovascular mortality in the
general population and in T2DM individuals [2–4]. Thus,* Correspondence: rosam.bruno@gmail.com
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unless otherwise stated.great attention has been paid to look for early biomarkers
able to predict CKD onset [5].
On regard of large arteries, endothelial dysfunction
and arterial stiffness are early vascular pathological
changes that might lead to end-organ dysfunction [6–8]
and are able to predict cardiovascular events in high-risk
patients such as those with diabetes [9, 10]. However,
the association between arterial stiffness and decline in
renal function in longitudinal studies is controversial.
Aortic pulse wave velocity (PWV), the gold standard
technique for measuring aortic stiffness, was independ-
ently associated with a further loss of renal function inThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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in the general population cohort of the Framingham
Heart Study [12]. Furthermore, in a cohort of 461
T2DM patients followed up to 5 years, carotid-femoral
PWV was an independent predictor of microalbuminuria
(MA) onset and correlated with annual change in esti-
mated glomerular filtration rate (eGFR) [13].
Renal resistive index (RI) is a duplex ultrasound-
derived parameter, related to renal arteriolosclerosis
[14], and it may represent an integrated index of arterial
compliance, pulsatility and downstream microvascular
impedance [15, 16]. Among its applications in the clin-
ical management of a number of renal conditions, high
RI has a negative prognostic value in T2DM patients in
terms of progression of renal disease [17]. However,
some limitations in its use and interpretation should be
acknowledged, and its clinical significance has been re-
cently questioned [18, 19].
A few years ago, we identified a new ultrasound-based
biomarker, which we called Dynamic renal Resistive
INdex (DRIN), consisting in the change in RI after sub-
lingual nitrate administration and conceivably represent-
ing an index of renal vasodilating capacity. DRIN is
altered in newly diagnosed, untreated hypertensive pa-
tients, and further compromised in T2DM patients with-
out renal damage [20]. DRIN, but not RI, correlated with
parameters of vascular function and arterial stiffness, be-
yond the effect of classical cardiovascular risk factors.
DRIN was related with metabolic and blood pressure
control in T2DM patients, and with arterial stiffness and
wave reflections in hypertensive individuals, suggesting
different routes of renal vascular damage accrual in the
early stages of the two conditions [20].
The aim of this pilot study has been to evaluate pro-
spectively whether DRIN, as well as other markers of
systemic vascular damage, is able to predict microalbu-




The original cohort [20] included 32 newly diagnosed
(<3 months), treatment-naive T2DM patients, defined
according to the American Diabetes Association criteria
and 49 never treated essential hypertensive patients
(EH). Modality of enrollment and inclusion/exclusion cri-
teria have been previously described [20]. Briefly, inclusion
criteria were: age between 40 and 70 years; written in-
formed consent; diagnosis of essential hypertension (for the
EH group) or type 2 diabetes (for the T2DM group)
within the previous 6 months, according to current
guidelines, absence of any micro or macrovascular com-
plications, normal albumin excretion rate in the previ-
ous six months, no previous or current treatment withantihypertensive or antidiabetic medications. The protocol
was approved by the local ethical committee and all
patients gave a written consent.
Experimental protocol: Visit 0
At Visit 0 the patients underwent a comprehensive
evaluation, including blood and urine samples collection,
baseline and dynamic renal RI, flow-mediated dilation of
the brachial artery (FMD) and carotid-femoral PWV and
Aix. A detailed description of the methods is present in
the published article regarding the cross-sectional evalu-
ation at Visit 0 [20].
Baseline and dynamic renal resistive index
The duplex ultrasound intraparenchimal renal scan
(MyLab 25, ESAOTE Florence, Italy) was performed by
one trained operator using a high resolution multifre-
quency Convex probe (2.5 - 4.5 MHz). Three velocimetric
measurements of the interlobar renal arteries were ob-
tained at baseline and five minutes after sublingual admin-
istration of glyceryl trinitrate 25 μg (GTN), at the end of
the brachial artery evaluation (see below), so that a single
GTN administration was given to each patient. RI was cal-
culated as: (systolic peak velocity – end diastolic velocity)/
systolic peak velocity. DRIN (%) was calculated as:
(postGTN RI - baseline RI) ×100/baseline RI [20, 21].
Endothelium-dependent and -independent vasodilation in
the brachial artery
Endothelium-dependent response was assessed by flow-
mediated dilation (FMD), as previously described [22].
Briefly, a pediatric cuff was positioned around the right
forearm and the right brachial artery was located and
scanned using a 10 MHz linear array transducer (MyLab
25, ESAOTE Florence, Italy). After 1-min baseline record-
ing, the cuff was inflated for 5 min at 300 mmHg and then
deflated to induce reactive hyperemia. Endothelium-
independent vasodilation was obtained by the sublingual
administration of 25 μg GTN [22]. Brachial artery diam-
eter and flow velocity were continuously monitored by
computerized edge detection system (Cardiovascular
Suite; Quipu srl, Italy) [23]. FMD and response to GTN
were calculated as the maximal percent increase in diam-
eter above baseline.
Arterial tonometry
Arterial tonometry (SphygmoCor, AtCor Medical, Sidney,
Australia) was performed according to the international
recommendations [6]. Central blood pressure was derived
from radial pressure waveform by means of a validated
transfer function and averaged on three measurements.
Augmented pressure was calculated as the difference be-
tween the second and the first systolic peak, and augmenta-
tion index (AIx) was calculated as the ratio between
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ized at a heart rate of 75 bpm. Time to reflection (TR) was
defined as the total travel time of the pulse-wave to the per-
iphery and its return. Carotid-femoral pulse wave velocity
(PWV) was calculated as the ratio of the surface distance
between the two recording sites (subtracted distance) and
wave transit time. In 57 out of 70 patients radial arterial to-
nometry and brachial BP were taken after GTN administra-
tion, during RI measurements, in order to collect central
BP and wave reflection variables.
Experimental protocol: Visit 1
27 out of the 32 T2DM and 43 of the 49 EH forming
the original cohort agreed to participate in the follow-up
and formed the population of the present prospective,
observational, pilot study.
Visit 1 took place after a mean period of 4.1 ± 0.6 years
from Visit 0 (range 3.4-5.1 years). Patients were asked to
refer to the Hypertension Outpatient Clinic after an over-
night fasting. A blood sample was drawn from an antecubi-
tal vein and fasting glucose, HbA1c, serum creatinine, total
and HDL cholesterol and triglycerides were measured by
standard techniques. eGFR was estimated using the CKD-
EPI formula [24]. Urinary albumin excretion was evaluated
as urine albumin to creatinine ratio (UACR) in two con-
secutive spot morning urine samples; when micro-
macroalbuminuria was detected, the result was confirmed
in a 24-h urine collection within the following four weeks.
Plasma nitrotyrosine was analyzed by chemiluminescence
(Nitrotyrosine Assay Kit, Merck Millipore; Merck KGaA,
Darmstadt, Germany), according to the manufacturer’s in-
structions, in blood samples collected during Visit 1 and in
frozen samples collected during Visit 0, since the previously
used Nitrotyrosine ELISA Test Kit (Cell Sciences, Canton,
MA, USA) [20] was no longer available. A detailed pharma-
cological and clinical history was collected, and a complete
clinical examination was performed. Clinic BP was then
measured (mean of at least two measurements in 5 min in
the supine position by an automatic sphygmomanometer –
OMRON M4). At Visit 1 patients underwent also baseline
and dynamic renal resistive index and arterial tonometry,
performed by the same modality of Visit 0.
The following renal clinical outcomes were considered:
 Microalbuminuria onset: defined as UACR ≥ 30 mg/g
present at Visit 1 and confirmed within 4 weeks;
 eGFR decline: defined when the slope of eGFR
was < −1 ml/min1.73 m2/year along the follow-up,
assuming the physiologic age-related GFR decline as
approximately 1 ml/min/year. eGFR slope was
defined as the regression coefficient between eGFR
and time in units of ml/min per 1.73 m2/year,
plotting at least three eGFR measurements during
the follow-up period [25].Statistical analysis
Statistical analysis was performed using NCSS 8 (NCSS,
Kaysville, Utah; USA). The results were expressed as
mean ± SD for normally distributed variables and as me-
dian (25 %-75 %) for not-normally distributed variables.
Differences between groups (T2DM vs EH; MA vs No
MA; eGFR decline vs No GFR decline) were analyzed
using t-test for normally distributed variables, and
Wilcoxon Rank Sum test for not normally distributed
variables; categorical variables were analyzed by χ2 test.
Analysis of covariance (ANCOVA) was used to analyze
differences in vascular variables between groups with fa-
vorable or unfavorable outcomes, considering age and
mean BP as covariates. The behavior of variables over
time in patients developing or not an unfavorable out-
come was assessed by repeated measures ANOVA, test-
ing two-factor (visit-outcome) interaction and using
Bonferroni test to analyze multiple comparisons. Re-
ceiver operating characteristic (ROC) analysis was per-
formed in order to identify the predictive value of PWV
and DRIN for renal outcomes. Cut-points selected were
those that yielded the greatest sum of sensitivity and
specificity. An explorative subgroup analysis was per-
formed separately in T2DM and EH, in order to ascer-
tain whether the predictive power of biomarkers might
be different in the two conditions. A p < 0.05 was con-
sidered significant.
Results
Clinical characteristics at Visit 0 and 1
Clinical characteristics of the two study groups at Visit 0
are summarized in Table 1. T2DM were significantly older
and had a higher BMI as compared to EH; as expected,
they showed higher levels of fasting glucose, HbA1c and
triglycerides. EH presented higher mean and diastolic BP
values. Median UACR, even within the normal range, was
higher in T2DM, while eGFR was similar.
RI and DRIN values were significantly higher in
T2DM as compared to EH (RI 0.66 ± 0.04 vs 0.58 ± 0.04,
p < 0.001; DRIN −5.9 ± 5.9 %, −10.1 ± 6.9 %, p = 0.03).
Conversely, PWV (8.6 ± 2.1 vs 8.0 ± 1.1 m/s, p = 0.22), AIX
(26 ± 15 vs 21 ± 11 %, p = 0.11), BA diameter (4.29 ± 0.63
vs 4.31 ± 0.75 mm, p = 0.91), FMD (3.9 ± 1.5 vs 5.3 ± 2.9 %,
p = 0.17) and GTN (5.7 ± 2.6 vs 5.5 ± 2.3 %, p = 0.84) were
similar in the two groups.
Clinical characteristics at Visit 1
Visit 1 took place after a mean period of 4.2 ± 0.6 years
from Visit 0 (range 3.4-5.1 years). While at Visit 0 all in-
dividuals were untreated, at Visit 1, 25 patients out of 27
in the T2DM group were on pharmacologic glucose-
lowering treatment, and 40 patients (13 in the T2DM
group and 27 in the EH group) were on BP-lowering
drugs. All patients on BP-lowering drugs at Visit 1 were
Table 1 Clinical characteristics of the study groups at visit 0 and visit 1
EH (n = 43) visit 0 EH (n = 43) visit 1 T2DM (n = 27) visit 0 T2DM (n = 27) visit 1
Age (years) 51.7 ± 8.0 - 60.0 ± 10.5* -
Men (n,%) 32 (74 %) - 14 (52 %) -
Smokers (n,%) 9 (21 %) - 5 (19 %) -
BMI (Kg/m2) 26.6 (24.6-31.1) 28.4 (25.1-30.1) 30.0 (27.9-36.1)* 29.2 (27.2-35.1)
Brachial systolic BP (mmHg) 142.7 ± 9.9 144.5 ± 17.9 139.8 ± 14.5 141.2 ± 10.7
Brachial diastolic BP (mmHg) 86.1 ± 8.1 86.9 ± 11.8 78.7 ± 8.8* 73.1 ± 9.4
Brachial PP (mmHg) 56.6 ± 8.1 57.6 ± 11.1 61.1 ± 16.6 68.2 ± 13.7
Mean BP (mmHg) 105.7 ± 7.9 107.1 ± 11.5 100.6 ± 7.9* 96.6 ± 7.6
Aortic systolic BP (mmHg) 131.5 ± 11.8 132.4 ± 13.0 128.6 ± 17.2 126.9 ± 10.1
Aortic PP (mmHg) 47.2 ± 13.7 45.2 ± 8.6 51.4 ± 16.4 52.9 ± 13.5
Heart rate (bpm) 65.8 ± 10.5 71.1 ± 10.4# 68.5 ± 12.6 68.6 ± 11.8
Fasting plasma glucose (mg/dl) 90 (86–95) 90 (86–96) 140 (119–183)* 114 (107–132)#
Hb1Ac (%) 5.2 (5.0-5.7) 5.4 (5.0-6.4) 6.9 (6.4-7.4)* 6.4 (6.1-7.1) #
Total cholesterol (mg/dl) 209 ± 34 206 ± 39 227 ± 53 183 ± 38#
LDL-cholesterol (mg/dl) 137 ± 36 127 ± 36 131 ± 57 107 ± 31
HDL-cholesterol (mg/dl) 50 ± 14 53 ± 12 50 ± 17 52 ± 13
Triglycerides (mg/dl) 104 (71–174) 108 (73–162) 164 (102–247) 131 (91–159)
Serum creatinine (mg/dl) 0.90 ± 0.17 0.91 ± 0.18 0.86 ± 0.21 0.85 ± 0.19
eGFR (ml/min/1.73 m2) 91.1 ± 13.7 86.9 ± 13.4 86.3 ± 15.1 84.4 ± 14.2
UACR (mg/g) 2.0 (0–5.9) 9.3 (5.7-18.4) # 6.6 (1.6-15.5)* 10.7 (3.8-44.8) #
Nitrotyrosine (μmol/l ) 9.8 ± 1.4 12.2 ± 3.2 # 13.1 ± 2.5* 11.9 ± 3.4
*p < 0.05 vs EH group
#p < 0.05 vs Visit 0
Table 2 Vascular characteristics according to albuminuria
outcome at visit 0 and visit 1 in the whole study group









RI 0.60 ± 0.06 0.64 ± 0.05 0.61 ± 0.06 0.67 ± 0.08*
DRIN (%) −10.6 ± 6.4 −2.8 ± 6.7* −5.5 ± 4.8# −4.5 ± 3.1
Aortic SBP
(mmHg)
127.0 ± 10.6 134.9 ± 23.0 130.3 ± 12.2 130.2 7.0
Aortic PP
(mmHg)
45.4 ± 10.1 52.4 ± 18.8 46.8 ± 11.0 54.9 ± 11.6
AIx (%) 26.7 ± 13.5 30.8 ± 10.0 27.1 ± 10.7 27.8 ± 10.6
TR (ms) 142 ± 19 128 ± 14* 142 ± 13 139 ± 6
Aix@75 (%) 21.6 ± 13.1 26.0 ± 11.0 22.7 ± 9.9 24.1 ± 8.6
PWV (m/s) 7.9 ± 1.5 9.9 ± 1.3* 8.5 ± 1.8 12.3 ± 2.9#
*p < 0.05 vs No MA group
#p < 0.05 vs Visit 0
Bruno et al. Cardiovascular Diabetology  (2015) 14:63 Page 4 of 9treated with a regimen including a renin-angiotensin
system (RAS)-blocker. Office BP during follow-up was
unchanged, with a borderline increase in brachial PP in
T2DM group (p = 0.07). Glucose control and total chol-
esterol levels were improved from Visit 0 to Visit 1 in
the T2DM subgroup. Serum creatinine and eGFR were
substantially unchanged over time, while median UACR
was significantly increased. According to the abovemen-
tioned definitions, at Visit 1 13 patients (9 T2DM) had
developed MA, while 27 patients (11 T2DM) showed
eGFR decline.
Clinical and vascular characteristics according to
albuminuria outcome
Incidence of MA was greater in the T2DM than in the
EH group (9 vs 4 patients, 33.3 vs 9.3 %, p = 0.005). In
the overall population, at baseline, patients developing
MA were older (62.2 ± 8.1 vs 53.4 ± 10.4 years, p = 0.03),
had higher UACR [15(10–23) vs 2(0–7) mg/g, p = 0.03]
and higher nytrotyrosine concentration (13.0 ± 2.7 vs
10.9 ± 2.45 μmol/l , p = 0.048) than those not developing
MA. Fasting blood glucose was higher at Visit 0 in pa-
tients developing MA [from 172(105–211) to 124(100–
141) mg/dl] than in those not [from 95(89–124) mg/dl
to 96(90–107) mg/dl], but reached similar values at Visit1 (p for interaction Visit-Outcome = 0.002). There was
no significant difference in RAS blockers use at Visit 1
between patients developing MA or not (78 % vs 53 %,
p = 0.17).
Baseline vascular characteristics according to MA out-
come are shown in Table 2 and Fig. 1. Among all the
Fig. 1 Box plots representing DRIN (a) e PWV (b) values at Visit 0 (in white) and Visit 1 (in grey) according to microalbuminuria outcome
Table 4 Baseline vascular characteristics according to
albuminuria outcome in the two subgroups
T2DM subgroup EH subgroup
No MA MA No MA MA
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higher in patients developing MA, while RI did not differ
significantly. Differences between groups remained signifi-
cant even after adding age and mean BP as covariates for
DRIN and PWV (unadjusted p value: 0.01 and 0.004 re-
spectively; adjusted p value: 0.04 and 0.04 respectively) but
not for TR (unadjusted p value 0.03; adjusted p value
0.28). No differences in baseline endothelium-dependent
and independent vasodilation of the brachial artery were
found in subjects with favorable or unfavorable MA out-
come (baseline BA diameter 4.2 ± 0.7 vs 4.7 ± 0.9; FMD
5.1 ± 3.6 vs 3.7 ± 2.3 %; GTN 5.4 ± 3.7 vs 4.2 ± 2.8 %; p = ns
for all). In the ROC analysis performed in the overall
population, both DRIN greater than −4.55 % or PWV
greater than 8.50 m/s were able to predict MA develop-
ment with a good sensitivity and specificity (Table 3).Table 3 ROC analysis of vascular variables at visit 0 for MA
development in the overall population and in the two subgroups
AUC Cut-off Sensitivity Specificity
Overall population DRIN 0.798 −4.55 % 0.84 0.71
PWV 0.838 8.50 m/s 0.82 1.00
RI 0.702 0.65 0.82 0.50
T2DM subgroup DRIN 0.800 −5.16 % 0.83 0.80
PWV 0.675 9.40 m/s 0.78 0.50
RI 0.404 0.69 0.92 0.16
HT subgroup DRIN 0.792 −7.69 % 0.69 1.00
PWV 0.919 8.60 m/s 0.96 1.00
RI 0.751 0.63 0.96 0.50We performed an explorative subgroup analysis in
T2DM and EH separately (Table 4). In the T2DM group,
baseline DRIN (−8.4 ± 4.1 vs −1.7 ± 7.8 %, p = 0.03) was
significantly higher in patients developing MA than in
those not. Conversely, in the EH group, baseline PWV
(10.5 ± 1.8 vs 7.8 ± 0.8 m/s, p = 0.0004) was significantly
higher in patients developing MA than in those not.
These data were confirmed by the ROC analysis: in the
diabetic sub-group DRIN was a better predictor than
PWV, while the opposite occurred in the hypertensive
subgroup (Table 3).(n = 18) (n = 9) (n = 39) (n = 4)
RI 0.66 ± 0.04 0.57 ± 0.04 0.57 ± 0.04 0.62 ± 0.05
DRIN (%) −8.4 ± 4.1 −1.7 ± 7.8* −11.6 ± 7.0 −5.7 ± 1.6
Aortic SBP
(mmHg)
124.7 ± 11.3 128.0 ± 10.3 128.0 ± 10.3 144.0 ± 25.4
Aortic PP
(mmHg)
47.5 ± 11.7 44.4 ± 9.3 44.4 ± 9.3 47.0 ± 14.1
AIx (%) 28.3 ± 16.7 25.9 ± 12.0 25.9 ± 12.0 22.5 ± 12.0
TR (ms) 134 ± 25 145 ± 15 145 ± 15 133 ± 30
Aix@75 (%) 24.3 ± 17.3 20.4 ± 10.8 20.4 ± 10.8 18.5 ± 14.8
PWV (m/s) 8.3 ± 2.5 7.8 ± 0.8 7.8 ± 0.8 10.6 ± 1.8*
BA diameter (mm) 4.2 ± 0.4 4.3 ± 0.8 4.3 ± 0.8 4.0 ± 0.3
FMD (%) 4.3 ± 1.3 5.6 ± 4.3 5.6 ± 4.3 4.6 ± 2.9
GTN (%) 6.3 ± 2.6 5.3 ± 3.7 5.3 ± 3.7 4.7 ± 5.4
*p < 0.05 vs No MA group
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istics over time according to MA outcome (Table 2). In
patients developing MA, DRIN, which was already al-
tered at Visit 0, was unchanged at Visit 1, while in pa-
tients not developing MA, a significant increase in
DRIN was observed; conversely, PWV showed a further
increase only in patients developing MA (Fig. 1).
Clinical and vascular characteristics according to
eGFR outcome
The proportion of patients showing eGFR decline > −1 ml/
min/year was similar in EH and T2DM group (16 vs 11 pa-
tients, 37.2 % vs 40.7 %, p = ns). In the overall population,
patients developing eGFR decline had higher baseline eGFR
(93 ± 16 vs 85 ± 11 ml/min1.73, p = 0.04) than those not,
while all the other clinical characteristics, including age and
nitrotyrosine levels, were similar in the two groups. BP was
similar over time in patients developing eGFR decline
(mean BP from 103 ± 8 to 103 ± 12 mmHg) and in those
not (mean BP from 102 ± 8 to 102 ± 14 mmHg; p for inter-
action Visit-Outcome = 0.86). The percentage of patients
receiving RAS blockers at Visit 1 was similar (62 % vs 56 %,
p = 0.66). Fasting blood glucose variation between Visit 0
and 1 was not significantly different in patients developing
eGFR decline [from 95(90–135 mg/dl) to 105(91–114)]
than in those not [from 96(88–130) to 90(87–110) mg/dl, p
for interaction Visit-Outcome =0.53].
Vascular characteristics according to eGFR outcome are
shown in Table 5. None of the variables studied was signifi-
cantly different between those with eGFR slope < −1 ml/
min/year during the follow up period and those not. No dif-
ferences in baseline endothelium-dependent and inde-
pendent vasodilation of the brachial artery emerged in
subjects without or with eGFR decline (baseline BA diam-
eter 4.3 ± 0.8 vs 4.5 ± 0.5 mm; FMD 5.3 ± 4.4 vs 4.0 ±
1.6 %; GTN 5.2 ± 3.7 vs 5.7 ± 2.6 %; p = ns for all).
Then we performed subgroup analysis in T2DM and
EH separately. In the T2DM group we did not find any
significant difference in vascular parameters between pa-
tients with different eGFR outcome. Conversely, in EH,Table 5 Vascular characteristics according to GFR outcome at visit 0
Visit 0
No GFR decline (n = 43) GFR decline
RI 0.61 ± 0.05 0.61 ± 0.06
DRIN (%) −9.7 ± 7.9 −6.8 ± 4.5
Aortic SBP (mmHg) 130.2 ± 12.7 129.5 ± 12.1
Aortic PP (mmHg) 49.5 ± 18.6 47.5 ± 10.2
AIx (%) 27.3 ± 13.0 27.9 ± 11.8
TR (ms) 136 ± 20 139 ± 17
Aix@75 (%) 23.4 ± 12.1 21.7 ± 12.4
PWV (m/s) 8.3 ± 1.5 8.1 ± 1.4DRIN (−5.8 ± 3.5 vs −12.5 ± 7.1 %, p = 0.002) and PWV
(8.4 ± 1.1 vs 7.6 ± 0.8 m/s, p = 0.04) were significantly
higher in patients whose eGFR declined than in those
not, while the other vascular variables were similar
(Table 5). Furthermore, in the EH group, nitrotyrosine
levels were higher in EH patients with steeper eGFR
slope (10.6 ± 1.6 vs 8.9 ± 0.9 μmol/L, p = 0.02), while no
difference in nitrotyrosine was found in the overall
population and in the T2DM group.
We did not observe any difference in the behavior of
vascular characteristics over time according to the slope
of eGFR decline (Table 5).GTN-induced systemic hemodynamic changes in relation
to DRIN
We analyzed brachial and central BP changes after GTN
administration, which were available at Visit 0 for 57 out
of 70 participants (Table 6), to verify the hypothesis of
DRIN dependence on GTN-induced changes in central
hemodynamics rather than on renal vasodilation.
GTN administration caused a similar reduction in bra-
chial and central PP. AIx was also significantly reduced.
GTN-induced absolute change in RI was related to abso-
lute change in central PP (r = 0.39, p = 0.009) and AIx (r =
0.32, p = 0.03), but not brachial PP (r = 0.18, p = 0.20).
GTN-induced percent change in RI (that is DRIN) was
not related to percent change in brachial or central PP
(r = −0.05, p = 0.70 and r = −0.07, p = 0.66 respectively) or
AIx (r = −0.20, p = 0.19). Nor absolute (−0.7 ± 13.1
vs −3.3 ± 7.8 mmHg, p = 0.57; 3.9 ± 12.6 vs −5.1 ± 10.0,
p = 0.11) neither percent changes in central PP and AIx
at Visit 0 (5.1 ± 30.3 vs −7.2 ± 18.6 %, p = 0.36; 19.6 ±
47.5 vs 1.5 ± 134.2 %, p = 0.06) were associated to
microalbuminuria development at Visit 1, though a
trend for significance was observed for AIx. GTN-
induced AIx percent changes at Visit 0 were not sig-
nificantly different between individuals developing or
not microalbuminuria, when age and mean BP were
added as covariates (p = 0.50).and visit 1 in the whole study group
Visit 1
(n = 27) No GFR decline (n = 43) GFR decline (n = 27)
0.62 ± 0.08 0.61 ± 0.05
−5.1 ± 4.6 −5.9 ± 4.3
130.5 ± 13.4 130.4 ± 12.2
49.1 ± 13.2 47.0 ± 9.2
24.0 ± 9.3 22.4 ± 9.4
138 ± 11 144 ± 12
23.4 ± 12.1 21.7 ± 12.4
8.8 ± 2.0 9.1 ± 2.9
Table 6 Systemic hemodynamic variables after acute







Brachial systolic BP (mmHg) 139.8 ± 12.6 134.3 ± 12.1 <0.0001
Brachial diastolic BP (mmHg) 82.3 ± 8.9 80.4 ± 8.6 0.02
Brachial PP (mmHg) 57.5 ± 11.7 53.9 ± 13.2 0.003
Aix (%) 27.4 ± 11.4 23.9 ± 13.0 0.02
Aix@75 (%) 23.7 ± 11.0 19.3 ± 10.8 0.007
Aortic systolic BP (mmHg) 127.6 ± 14.6 122.8 ± 14.2 0.0006
Aortic PP (mmHg) 45.0 ± 12.7 41.5 ± 13.5 0.008
HR (bpm) 67.4 ± 10.6 65.8 ± 9.7 0.08
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CKD, occurring in 25-40 % of T2DM patients [3], ac-
counts for the majority of the diabetes-related morbidity
and mortality [26–28]. In hypertensive patients CKD is
less frequent [29] but equally deleterious for the global
prognosis [30]. For these reasons, the development of a
non-invasive test able to predict the onset of any impair-
ment of renal function is appealing. In this pilot, proof-
of-concept study we tested the ability of a novel test,
DRIN, in predicting microalbuminuria onset and GFR de-
cline in a cohort of newly diagnosed, drug-naive patients
with hypertension or T2DM. Furthermore, we compared
this novel marker with more established non-invasive bio-
markers of renal and systemic vascular damage.
Predictive role of DRIN for microalbuminuria
development
The main finding of this study is that patients develop-
ing microalbuminuria after a follow-up of about 4 years
had at baseline higher values of PWV and DRIN. Inter-
estingly, the association between these vascular bio-
markers and renal outcome seems to be disease-specific:
DRIN was the best predictor of microalbuminuria onset
in T2DM patients, PWV in hypertensive patients.
It has been demonstrated that high resting RI (>0.80)
predicts rapid eGFR decline in long-standing microalbu-
minuric hypertensive T2DM patients [31]. This is not
necessarily in contrast with the results of our study, en-
rolling only newly diagnosed T2DM patients, all with
normal albumin excretion and normal RI at baseline. In
fact, we demonstrated that renal vasodilating capacity is
reduced in T2DM patients before the onset of estab-
lished renal damage and in the presence of normal RI
values [20]. In this early phase, it is conceivable that
functional, rather than structural alterations might be
already present, indicating a subclinical stage of renal
damage. Several hypotheses on the pathogenesis of
microalbuminuria in T2DM have been suggested, many
of them involving alterations of the glomerularendothelium [32, 33]. DRIN is a simple vascular reactiv-
ity test, exploring the renal district, which might unmask
subclinical vascular alterations possibly responsible for
albuminuria development. There has been a recent large
debate on the clinical significance of RI, with new evi-
dence indicating that this index might reflect systemic
hemodynamic status and arterial impedance rather than
a truly “renal” condition [18]. Following this hypothesis, the
correlation between RI and microalbuminuria found in
some studies may reflect the effect of increased pulsatility
in the aorta, leading to microvascular damage over time
[19]. Nitrates are known to have a significantly greater im-
pact on hemodynamic pulsatile load, and in particular on
wave reflection [8], thus it is mandatory to determine
whether DRIN reflects a systemic rather than a renal condi-
tion, as suggested for RI. Our data support the hypothesis
that GTN-induced changes in central hemodynamics (rep-
resented by central PP and AIx) are major determinants of
DRIN, but do not retain any predictive value for renal out-
comes, suggesting a renal-specific significance for DRIN.
Furthermore, in the present study we demonstrated that, in
comparison to PWV, DRIN retains a greater predictive
value for microalbuminuria onset in T2DM, suggesting that
RI changes after nitrate administration may overcome the
shortcomings highlighted for RI.
DRIN and PWV changes during follow-up
In this study we explored the possible clinical signifi-
cance of variations of vascular biomarkers over time.
Conceivably DRIN may play a role in prediction of incipi-
ent nephropathy, particularly in T2DM, while its ability to
serve as a marker of damage accrual is less likely, since it
is already severely altered in newly diagnosed patients and
it cannot show further deterioration during follow-up.
Thus, we might speculate that the predictive value of
DRIN is present only at the very beginning of the diabetic
and hypertensive disease, since DRIN rapidly deteriorates
over time in all individuals regardless of renal prognosis.
DRIN, being an early marker of renal involvement, prob-
ably loses its usefulness with disease progression. On the
other hand, PWV not only is early increased, but also pro-
gresses faster in patients developing microalbuminuria,
proposing arterial stiffness as both a cause and a conse-
quence of renal damage accrual, particularly in hyperten-
sive individuals. In the hypertensive subgroup PWV, but
not DRIN, was higher at baseline in those developing
microalbuminuria, confirming previous cross-sectional
observations [34, 35] and suggesting that mechanisms re-
sponsible for its onset are different for hypertension or
type 2 diabetes [36]. In particular, hypertension-related
large artery stiffness, reducing the buffering capacity of the
arterial tree, exposes peripheral circulation and small ves-
sels to increased flow and pressure pulsatility, thus indu-
cing microvascular damage [37].
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Vascular biomarkers were not able to predict GFR de-
cline neither in the overall study population nor in the
T2DM subgroup. This finding might be due to the slow
rate of GFR progression in our population, which was
modest and similar in the hypertensive and T2DM
groups, in agreement with the short disease duration
and the fairly good metabolic and blood pressure con-
trol. However the apparent discrepancy between the
demonstrated predictive role of vascular biomarkers for
MA onset but not for eGFR outcome in diabetic individ-
uals is not surprising, since recent evidence suggest that
MA onset and eGFR decline often do not coexist [38].
Thus we may speculate that specific pathophysiological
mechanisms are involved in the development of the
emerging phenotype of normoalbuminuric eGFR decline
[38]. It is also interesting to note that the only predictor
of eGFR decline was a higher eGFR at baseline, in agree-
ment with the hypothesis that hyperfiltration may con-
tribute to diabetic nephropathy onset [39].
DRIN and PWV, as well as nitrotyrosine, are early
compromised in EH patients with steeper eGFR slope,
suggesting that among mechanisms of renal damage de-
velopment in hypertension, local and systemic vascular
alterations, together with increased oxidative stress, may
play a crucial role. It is well known from experimental
studies that renal oxidative stress contributes to renal
vasoconstriction and ischemia, thus favoring hyperten-
sion development and renal function decline [40]. Note-
worthy, we excluded major systemic hemodynamic
variations as a determinant of eGFR decline in hyperten-
sive patients, since BP behavior over time was similar in
patients experiencing eGFR decline and in those not,
and a similar proportion of patients had started a treat-
ment with BP-lowering drugs during follow-up in the two
groups with different outcomes. If our observations will be
confirmed in larger cohorts of individuals, DRIN might be
potentially useful for the early identification of hyperten-
sive patients at risk of developing renal impairment.
Limitations
We must acknowledge as limitations of this study the
relatively low sample size, which did not allow us to ver-
ify the independent predictive value of DRIN and to fully
assess its clinical significance in the diabetic and hyper-
tensive subgroup. In particular, given the small size of
the T2DM group, it was not possible to perform a multi-
variate analysis and demonstrate whether the predictive
role of DRIN for microalbuminuria onset is independent
of other well-known determinants such as glycemic con-
trol and baseline UACR levels. Further prospective, ad-
equately powered studies, should test the additive
predictive value of DRIN on top of these clinical charac-
teristics, validating this test to be introduced in theclinical practice. Finally, the use of estimated GFR in-
stead of its direct measurement might have made less
accurate results regarding renal function decline.
Conclusions
This proof-of-concept, prospective study demonstrates
for the first time that renal vasodilating capacity is early
reduced in patients with T2DM and EH at risk of devel-
oping incipient nephropathy. DRIN appears to be super-
ior to systemic vascular biomarkers such as PWV for
prediction of microalbuminuria onset, when measured in
newly diagnosed, untreated patients with T2DM, since it
probably retains a clinical significance that is specific for
the kidney. Moreover, this study highlights the importance
of local vascular mechanisms in the pathogenesis of CKD
in both EH and T2DM. Larger prospective studies are
needed to ascertain whether DRIN has an additive predict-
ive value in comparison to clinical predictors of CKD, as
well as its usefulness in the clinical setting.
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